Results 141 to 150 of about 114,702 (262)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers

Medical Science Monitor, 2019
Background Diabetes causes damage to the soft tissue and bone structure of the foot, referred to as “diabetic foot”. Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor, and the role and mechanism of ibrutinib on the diabetic foot have not been ...
Xue-min Yang, Zhenhao Cao, Peigang Wu, Zhong Li   +3 more
semanticscholar   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

NADPH oxidase 2 inhibitor GSK2795039 exerts antiplatelet and antithrombotic activity

Scientific Reports
Reactive oxygen species (ROS) production by NADPH oxidase (NOX) is a key promoter of platelet activation, making NOX inhibition an attractive antiplatelet strategy.
Eun Bee Oh, Yun Jeong Kong, Taeil Kim, Joara Jang, Hyunseong Yu, Ji Won Park, Solee Kim, Taeryeong Kim, Jisue Sohn, Tong-Shin Chang   +9 more
doaj   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

ImmunoTargets and Therapy, 2014
Jon E Arnason,1 Jennifer R Brown21Beth Israel Deaconess Medical Center, 2CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL) is the most common ...
Arnason JE, Brown JR
doaj  

Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate

Therapeutic Advances in Hematology
This is a case of hemophagocytic intravascular large B-cell lymphoma (IVLBCL) with central nervous system (CNS) involvement. Although R-CHOP chemotherapy regimen has been shown significant improvement in survival rate.
Fangfei Shao, Wei Su, Xiujie Zhao, Jianping He, Xiaofen Wang, Feng Guo, Haowen Xiao   +6 more
doaj   +1 more source

Ex vivo study of the effect of an anti-proliferative drug in Chronic Lymphocytic Leukemia cells mimicking proliferative niches microenvironment [PDF]

, 2013
Curs 2012 ...
Aguiló García, Meritxell
core  

Triplet regimens for frontline treatment of CLL—Great company or just a crowd?

HemaSphere
Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI).
Sean McKeague, John F. Seymour
doaj   +1 more source

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Haematologica, 2022
Jonathan J. Pinney, Sara K. Blick-Nitko, Andrea M. Baran, Derick R. Peterson, Hannah E. Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R. Van DerMeid, Paul M. Barr, Clive S. Zent, Michael R. Elliott, Charles C. Chu   +11 more
doaj   +1 more source

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

Journal of Blood Medicine, 2019
Aristea-Maria Papanota,* Ioannis Ntanasis-Stathopoulos,* Efstathios Kastritis, Meletios A Dimopoulos, Maria GavriatopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital,
Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA, Gavriatopoulou M   +4 more
doaj